Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by MeiraGTx
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
August 12, 2024
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
August 12, 2024
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
May 09, 2024
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx to Participate in Upcoming Investor Conferences
April 24, 2024
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
April 18, 2024
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
March 14, 2024
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
February 13, 2024
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
December 21, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx to Participate in Upcoming Investor Conferences
November 21, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
November 14, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities
October 30, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
October 24, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Reports Second Quarter 2023 Financial and Operational Results
August 10, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology
August 01, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing
July 19, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
June 27, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,
June 22, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting
May 16, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Reports First Quarter 2023 Financial and Operational Results
May 11, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces $60 Million Private Placement of Ordinary Shares
May 03, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
April 21, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx to Participate in Upcoming Investor Conferences
April 20, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
March 14, 2023
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
December 13, 2022
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022
December 08, 2022
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx to Participate in Upcoming Investor Conferences
November 22, 2022
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.
November 10, 2022
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress
October 04, 2022
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)
October 01, 2022
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.